AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30540619 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy for 20 sessions.
Number of subjects: 27
Study 30540619 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented EMG-triggered electrical stimulation therapy.
Number of subjects: 27
Study 30518430 — intervention group
Group type: EXPERIMENTAL
Intervention: NET intervention
Number of subjects: 1943
Study 30518430 — intervention group
Group type: COMPARATOR
Intervention: Control (passive dissemination of guidelines)
Number of subjects: 1943
Study 27131100 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute apple juice/preferred fluids (n=323)
Number of subjects: 647
Study 27131100 — intervention group
Group type: COMPARATOR
Intervention: Electrolyte maintenance solution (n=324)
Number of subjects: 647
Study 24456217 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 5 mg/day or 10 mg/day
Number of subjects: 152
Study 24456217 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin
Number of subjects: 152
Study 22301846 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPC+RIPostC (n=35)
Number of subjects: 70
Study 22301846 — intervention group
Group type: COMPARATOR
Intervention: Control (n=35)
Number of subjects: 70
Study 20618936 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation
Number of subjects: 47
Study 20618936 — intervention group
Group type: EXPERIMENTAL
Intervention: Activator instrument
Number of subjects: 47
Study 20618936 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisation
Number of subjects: 47
Study 20618936 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 47
Study 17924246 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal counselling (IPC)
Number of subjects: 117
Study 17924246 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 117
Study 16192591 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 50 mg/m² and Docetaxel 75 mg/m² (AT)
Number of subjects: 216
Study 16192591 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil 500 mg/m², Doxorubicin 50 mg/m², and Cyclophosphamide 500 mg/m² (FAC)
Number of subjects: 216
Study 12047485 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (0.7 mg kg(‐1))
Number of subjects: 12
Study 12047485 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.375 mg kg(‐1))
Number of subjects: 12
Study 12047485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10091823 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (300 mg intravenously over 1 h, followed by 20 mg/kg over the next 24 h plus 600 mg orally, in three doses, for 1 week, then 400 mg/day orally, for three weeks)
Number of subjects: 101
Study 10091823 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (2 mg/kg intravenously over 15 min, followed by 10 mg/kg over 24 h and then 450 mg/day orally, for one month)
Number of subjects: 101
Study 10091823 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 101
Study 8543508 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy for sexually abused children
Number of subjects: 29
Study 8543508 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy
Number of subjects: 29
Study 8543508 — intervention group
Group type: EXPERIMENTAL
Intervention: Future sexual abuse therapy outcome research considerations
Number of subjects: 29
Study 2407764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornithine alpha-ketoglutarate (OKG) 10 g (3.6 g alpha KG and 6.4 g ORN)
Number of subjects: 6
Study 2407764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornithine hydrochloride 6.4 g
Number of subjects: 6
Study 2407764 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alpha-ketoglutarate 3.6 g
Number of subjects: 6
Study 373415 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Histidine, 4 g/day
Number of subjects: 8
Study 373415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7109499 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC/FMC plus 5 mg/m2 Corynebacterium parvum (CP) subcutaneously on day 1
Number of subjects: 156
Study 7109499 — intervention group
Group type: COMPARATOR
Intervention: VAC/FMC
Number of subjects: 156
Study 7109499 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC/FMC plus CP
Number of subjects: 156
Study 30917820 — intervention group
Group type: COMPARATOR
Intervention: Checklist (CL)
Number of subjects: 64
Study 30917820 — intervention group
Group type: EXPERIMENTAL
Intervention: Group (G)
Number of subjects: 64
Study 30917820 — intervention group
Group type: EXPERIMENTAL
Intervention: Student Tutor (ST)
Number of subjects: 64
Study 30917820 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher (T)
Number of subjects: 64
Study 30448170 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB)
Number of subjects: 200
Study 30448170 — intervention group
Group type: COMPARATOR
Intervention: Uncoated Balloon (PTA)
Number of subjects: 200
Study 27346756 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention (usual care + WHO's contraception initiation protocol + financial incentives)
Number of subjects: 31
Study 27346756 — intervention group
Group type: COMPARATOR
Intervention: Usual care (condoms, emergency contraception, referral to local providers)
Number of subjects: 31
Study 25149596 — intervention group
Group type: EXPERIMENTAL
Intervention: 50mg ipragliflozin
Number of subjects: 30
Study 25149596 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mg ipragliflozin
Number of subjects: 30
Study 25149596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21822934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 10% caprylate-chromatography purified immunoglobulin
Number of subjects: 0
Study 21822934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19348602 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac sodium (BF) 0.1% ophthalmic solution with disodium cromoglycate (DSCG) 2.0%
Number of subjects: 86
Study 19348602 — intervention group
Group type: COMPARATOR
Intervention: Fluorometholone (FML) 0.02% ophthalmic suspension with disodium cromoglycate (DSCG) 2.0%
Number of subjects: 86
Study 19348602 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference for concomitant treatment
Number of subjects: 86
Study 19348602 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient's global evaluation
Number of subjects: 86
Study 17472472 — intervention group
Group type: EXPERIMENTAL
Intervention: Seaweed (Alaria esculenta), 5 g/day for 7 weeks
Number of subjects: 25
Study 17472472 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate, 141.3 mg of isoflavones/day for the last week of each treatment arm
Number of subjects: 25
Study 17472472 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 5 g/day for 7 weeks
Number of subjects: 25
Study 16007329 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular sunlight exposure (3615 minutes/year)
Number of subjects: 264
Study 16007329 — intervention group
Group type: COMPARATOR
Intervention: Sunlight deprivation
Number of subjects: 264
Study 11981081 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (6 g/day)
Number of subjects: 86
Study 11981081 — intervention group
Group type: COMPARATOR
Intervention: Soy oil (control)
Number of subjects: 86
Study 10512898 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors including blood pressure, blood cholesterol, glucose, respiratory function, cardiothoracic ratio, smoking habit, height, body mass index, age, preexisting coronary heart disease, and diabetes.
Number of subjects: 15406
Study 10512898 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose levels in nondiabetics.
Number of subjects: 15406
Study 10512898 — intervention group
Group type: COMPARATOR
Intervention: Former smokers.
Number of subjects: 15406
Study 10512898 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex-specific multivariate models.
Number of subjects: 15406
Study 7726397 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 6 mg.kg‐1.h‐1
Number of subjects: 18
Study 7726397 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 12 mg.kg‐1.h‐1
Number of subjects: 18
Study 2074175 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for restoration of venous patency and valvular function
Number of subjects: 49
Study 2074175 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment with heparin, oral anticoagulants, and compression stockings
Number of subjects: 49
Study 2074175 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for ilio-femoral DVT
Number of subjects: 49
Study 2074175 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment for ilio-femoral DVT
Number of subjects: 49
Study 7004557 — intervention group
Group type: EXPERIMENTAL
Intervention: Op-Site Skin Closure
Number of subjects: 110
Study 7004557 — intervention group
Group type: COMPARATOR
Intervention: Interrupted nylon sutures
Number of subjects: 110
Study 7004557 — intervention group
Group type: COMPARATOR
Intervention: Michel clips
Number of subjects: 110
Study 31870935 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast consumption
Number of subjects: 23
Study 31870935 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (1.2g·min‐1 glucose)
Number of subjects: 23
Study 31870935 — intervention group
Group type: COMPARATOR
Intervention: Breakfast omission
Number of subjects: 23
Study 31870935 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 23
Study 31424243 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic health warning posters (GWPs) displayed near the check-out area (n = 334)
Number of subjects: 441
Study 31424243 — intervention group
Group type: COMPARATOR
Intervention: No graphic health warning posters (status quo; n = 107)
Number of subjects: 441
Study 28114650 — intervention group
Group type: COMPARATOR
Intervention: Beach umbrella
Number of subjects: 81
Study 28114650 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen with SPF 100
Number of subjects: 81
Study 25828648 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine delivered with the Tx360 device
Number of subjects: 41
Study 25828648 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 41
Study 23743741 — intervention group
Group type: EXPERIMENTAL
Intervention: SUS Group
Number of subjects: 174
Study 23743741 — intervention group
Group type: COMPARATOR
Intervention: Streamline Group
Number of subjects: 174
Study 20842109 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg, vitamin C 1 g, and vitamin E 1,000 IU
Number of subjects: 1005
Study 20842109 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 1005
Study 19959730 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback in the form of video playback of driving performance
Number of subjects: 30
Study 19959730 — intervention group
Group type: COMPARATOR
Intervention: No feedback (Control group)
Number of subjects: 30
Study 19959730 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary mobile phone task during driving simulation
Number of subjects: 30
Study 17650804 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiangzhuo Huoxue Yishen Decoction (JHYD) combined with Finbid and allopurinol
Number of subjects: 90
Study 17650804 — intervention group
Group type: COMPARATOR
Intervention: Finbid and allopurinol (Control)
Number of subjects: 90
Study 15565596 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus preoperative treatment with recombinant human IL‐2 (34 patients)
Number of subjects: 69
Study 15565596 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (35 patients)
Number of subjects: 69
Study 12445025 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg orally each morning (07.00 h)
Number of subjects: 24
Study 12445025 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg orally each evening (18.00 h)
Number of subjects: 24
Study 10662482 — intervention group
Group type: EXPERIMENTAL
Intervention: Coformulation of low dose aspirin plus modified-release dipyridamole
Number of subjects: 1000
Study 10662482 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 1000
Study 10662482 — intervention group
Group type: COMPARATOR
Intervention: Modified-release dipyridamole
Number of subjects: 1000
Study 10662482 — intervention group
Group type: COMPARATOR
Intervention: No antiplatelet therapy
Number of subjects: 1000
Study 7474243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 2652) received estimates of likelihood of 6-month survival, outcomes of CPR, and functional disability at 2 months; a trained nurse facilitated communication and advance care planning.
Number of subjects: 9105
Study 7474243 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 2152)
Number of subjects: 9105
Study 2304776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A treatment for 4 months
Number of subjects: 43
Study 2304776 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 2304776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A treatment
Number of subjects: 43
Study 6775296 — intervention group
Group type: EXPERIMENTAL
Intervention: isosorbide dinitrate (ID) 5 mg
Number of subjects: 10
Study 6775296 — intervention group
Group type: EXPERIMENTAL
Intervention: nitroglycerin microcapsules (NGMC) 7.5 mg
Number of subjects: 10
Study 6775296 — intervention group
Group type: EXPERIMENTAL
Intervention: pentaerythritol tetranitrate (PETN) 160 mg
Number of subjects: 10
Study 6775296 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 30496299 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐DNA intradermal priming regimens (Group I: 2x0.1mL [3mg/mL], Group II: 2x0.1mL [3mg/mL] plus electroporation, Group III: 1x0.1mL [6mg/mL] plus electroporation)
Number of subjects: 191
Study 30496299 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐MVA administered with or without CN54rgp140/GLA‐AF
Number of subjects: 191
Study 30496299 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 191
Study 26399404 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime ingestion of hypertension medications
Number of subjects: 2012
Study 26399404 — intervention group
Group type: COMPARATOR
Intervention: Morning ingestion of hypertension medications
Number of subjects: 2012
Study 24788781 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly household food basket (FB) plus nutrition education (NE)
Number of subjects: 400
Study 24788781 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education (NE) alone
Number of subjects: 400
Study 23071212 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg daily)
Number of subjects: 256
Study 23071212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 20196651 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiologic TB test
Number of subjects: 584
Study 20196651 — intervention group
Group type: EXPERIMENTAL
Intervention: History of TB treatment
Number of subjects: 584
Study 20196651 — intervention group
Group type: COMPARATOR
Intervention: Smear technique
Number of subjects: 584
Study 19137863 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (tetracaine 0.5% eye drops and preservative free lidocaine 2% intracamerally)
Number of subjects: 564
Study 19137863 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar anesthesia (4 mL lidocaine 2% into the retrobulbar space)
Number of subjects: 564
Study 19137863 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Topical and Retrobulbar)
Number of subjects: 564
Study 15771597 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin therapy
Number of subjects: 14
Study 12466572 — intervention group
Group type: EXPERIMENTAL
Intervention: Deworming (anthelmintics)
Number of subjects: 85
Study 12466572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 10760336 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat vegetarian diet (10% of energy from fat) for 2 menstrual cycles
Number of subjects: 35
Study 10760336 — intervention group
Group type: COMPARATOR
Intervention: Customary diet with placebo pill for 2 menstrual cycles
Number of subjects: 35
Study 8558188 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 800 mg/d orally
Number of subjects: 243
Study 8558188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 1829865 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 400 micrograms
Number of subjects: 188
Study 1829865 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 80 micrograms
Number of subjects: 188
Study 6407453 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/day)
Number of subjects: 10
Study 6407453 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (180 mg/day)
Number of subjects: 10
Study 6407453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6407453 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and Diltiazem (combined)
Number of subjects: 10
Study 31637972 — intervention group
Group type: EXPERIMENTAL
Intervention: EXTRAS
Number of subjects: 573
Study 31637972 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 573
Study 27638452 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (not specified dosage or duration)
Number of subjects: 560
Study 27638452 — intervention group
Group type: COMPARATOR
Intervention: Consenting patients (control group)
Number of subjects: 560
Study 26759155 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (12-week duration)
Number of subjects: 16
Study 26759155 — intervention group
Group type: COMPARATOR
Intervention: Control (non-training)
Number of subjects: 16
Study 24841866 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Behavior Therapy (FBT)
Number of subjects: 72
Study 24841866 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 72
Study 23197280 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EG, n=91)
Number of subjects: 169
Study 20613691 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplugs (PLUG)
Number of subjects: 100
Study 20613691 — intervention group
Group type: COMPARATOR
Intervention: No earplugs (noPLUG)
Number of subjects: 100
Study 17617527 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly intravenous cisplatin at 40 mg/m2 for 6 weeks in combination with radiation therapy (RT)
Number of subjects: 0
Study 17617527 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone
Number of subjects: 0
Study 16228060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (KCZ) administered during the stimulation phase to 28 patients.
Number of subjects: 58
Study 16228060 — intervention group
Group type: COMPARATOR
Intervention: Control group of 30 patients not receiving KCZ.
Number of subjects: 58
Study 11871848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive ergonomics
Number of subjects: 124
Study 11871848 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic education
Number of subjects: 124
Study 11871848 — intervention group
Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 124
Study 10217001 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drainage removed after 12 hours
Number of subjects: 3
Study 10217001 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drainage removed after 24 hours
Number of subjects: 3
Study 10217001 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drainage removed after 48 hours
Number of subjects: 3
Study 7674882 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoneutral water (TW) at 50 W for 40 rev.min‐1
Number of subjects: 9
Study 7674882 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoneutral water (TW) at 100 W for 40 rev.min‐1
Number of subjects: 9
Study 7674882 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoneutral air (TA) at 50 W for 40 rev.min‐1
Number of subjects: 9
Study 7674882 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoneutral air (TA) at 50 W for 50 rev.min‐1
Number of subjects: 9
Study 8245329 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes
Number of subjects: 11667
Study 8245329 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninsulin-dependent diabetes
Number of subjects: 11667
Study 8245329 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 11667
Study 8245329 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality risk
Number of subjects: 11667
Study 8245329 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge prognosis
Number of subjects: 11667
Study 3516396 — intervention group
Group type: COMPARATOR
Intervention: 5-FU and carmustine (FB)
Number of subjects: 77
Study 3516396 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU, carmustine, and doxorubicin (FAB)
Number of subjects: 77
Study 3516396 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial remission
Number of subjects: 77
Study 3516396 — intervention group
Group type: EXPERIMENTAL
Intervention: No change
Number of subjects: 77
Study 3516396 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive disease
Number of subjects: 77
Study 30613055 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated psychoeducational program (individual face-to-face education and telephone-delivered health-coaching sessions)
Number of subjects: 47
Study 30613055 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated psychoeducational program
Number of subjects: 47
Study 30613055 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 47
Study 27062538 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol mixed with energy drink (AMED)
Number of subjects: 56
Study 27062538 — intervention group
Group type: COMPARATOR
Intervention: Alcohol only (AO)
Number of subjects: 56
Study 25013089 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI with distal protection
Number of subjects: 591
Study 25013089 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI without distal protection
Number of subjects: 591